Phase I dose escalation trial of Lapatinib in combination with trastuzumab

Phase I results show that combining 1000 mg lapatinib and weekly trastuzumab is well tolerated

Topically applied TG-100572 suppresses retinal vascular permeability

Targegen’s TG-100572 has been found to be effective at suppressing retinal vascular permeability in rabbits and mice

Everolimus extends time without tumor growth in advanced kidney cancer

mTor inhibitor RAD-001 (everolimus) has been shown  to significantly extended the time without tumor growth in patients with advanced kidney cancer who have failed standard therapies.